Jack Talley, BS

Jack V. Talley is a pharmaceutical management professional with more than 30 years of experience in the industry. He has taken three companies successfully public. He has been responsible for more than 20 equity issuances in both the private and public sectors raising in aggregate in excess of $300 million. Two of the three companies he has taken public have been successfully sold, the third is still independent. He has been responsible for numerous business development transactions and has secured product approvals in both Europe and the United States. Previously he was the CEO, President of Actinium Pharmaceuticals, Inc. (API) which he took public. Mr. Talley joined API from President, Chief Executive Officer and Director at EpiCept Corporation which he also took public. Prior to EpiCept, Mr. Talley led Penwest Ltd.'s efforts in its IPO spin-off and served as President and Chief Operating Officer of Penwest Pharmaceuticals. Penwest was eventually acquired by Endo. Mr. Talley started his career at Sterling Drug Inc., where he was responsible for all U.S. marketing activities for prescription drugs when the company was merged with Sanofi, he launched various new pharmaceutical products and.. Mr. Talley received his B.S. in Chemistry from the University of Connecticut.